Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FRBV7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,988
Award facts
- Contract value 100% obligated
- $19,988.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at approximately $20K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EXPAREL 266 mg/20 mL vials. This delivery order was issued under a firm fixed-price contract structure with an ultimate completion date of December 30, 2025. The award carries no set-aside designation, indicating DMS Pharmaceutical Group competed successfully in an unrestricted federal procurement environment. EXPAREL is a specialty surgical product used for local anesthesia and pain management, reflecting the company's capabilities in supplying specialized pharmaceutical and medical products to Department of Defense healthcare operations.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, designated SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. That master contract, awarded in November 2025 with a ceiling value of $500M and completion date of December 31, 2036, positions DMS Pharmaceutical Group as a critical regional pharmaceutical supplier for DoD military healthcare facilities worldwide. The PPV-G GEN V program is part of the broader $30.3 billion pharmaceutical procurement strategy designed to ensure consistent supply of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support Department of Defense medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FRBV7?
SPE2DR26FRBV7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FRBV7 worth?
The government has obligated $19,988 on SPE2DR26FRBV7.
Is contract SPE2DR26FRBV7 an order under another contract?
Yes. SPE2DR26FRBV7 is a delivery order under SPE2DR25D9206, an indefinite delivery contract.
Was contract SPE2DR26FRBV7 competed?
The extent of competition for SPE2DR26FRBV7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award